Skip to main content

Table 1 Patient clinicopathological characteristics and SLFN11 expression

From: High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment

   SLFN11Low SLFN11High P
Age (y)   55.72 ± 12.48 57.68 ± 9.98 0.351
Sex Male 112 21  
  Female 85 19 0.727
Site Left 43 4  
  Right 154 36 0.126
Grade Well/Moderate 139 37  
  Poor/Undifferentiated 58 3 0.003
TNM stage II 65 23  
  III 132 17 0.006
KRASa Wild type 136 23  
  Mutation 54 12 0.545
CEA(ng/ml)a   8.6 ± 17.57 10.34 ± 13.63 0.601
  1. a KRAS data was available in 225 patients, CEA data was available in 200 patients